{"disease":{"id":"relapsed-or-refractory-multiple-myeloma-combination-therapy","name":"relapsed or refractory multiple myeloma combination therapy"},"drugs":{"marketed":[{"drug_id":"teclistamab","indication_name":"Relapsed or Refractory Multiple Myeloma (Combination Therapy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bcmaxcd3","generic_name":"TECLISTAMAB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"CD3, BCMA","drug_class":"","quality_score":67,"revenue":"400","mechanism":"Teclistamab-cqyv activates T-cells by binding to CD3 and BCMA, leading to the lysis of multiple myeloma cells."},{"drug_id":"teclistamab-cqyv","indication_name":"Relapsed or Refractory Multiple Myeloma (Combination Therapy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TECVAYLI","generic_name":"TECLISTAMAB-CQYV","company_name":"JANSSEN BIOTECH","drug_phase":"marketed","molecular_target":"Tumor necrosis factor receptor superfamily member 17, T-cell surface glycoprotein CD3","drug_class":"","quality_score":35,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}